Travere Therapeutics Files 8-K, Updates Corporate Address
Ticker: TVTX · Form: 8-K · Filed: Mar 17, 2025 · CIK: 1438533
| Field | Detail |
|---|---|
| Company | Travere Therapeutics, Inc. (TVTX) |
| Form Type | 8-K |
| Filed Date | Mar 17, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-update, address-change
Related Tickers: TVTX
TL;DR
Travere Therapeutics (TVTX) moved offices, formerly Retrophin.
AI Summary
On March 17, 2025, Travere Therapeutics, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 3611 Valley Centre Drive, Suite 300, San Diego, CA 92130. The company was formerly known as Retrophin, Inc. and Desert Gateway, Inc.
Why It Matters
This filing updates the official contact and operational address for Travere Therapeutics, Inc., which is important for regulatory compliance and investor communication.
Risk Assessment
Risk Level: low — The filing is a routine corporate update regarding office location and does not contain material financial or operational news.
Key Players & Entities
- Travere Therapeutics, Inc. (company) — Registrant
- Retrophin, Inc. (company) — Former company name
- Desert Gateway, Inc. (company) — Former company name
- 3611 Valley Centre Drive, Suite 300, San Diego, CA 92130 (location) — New Principal Executive Offices
FAQ
What is the new principal executive office address for Travere Therapeutics, Inc.?
The new principal executive office address is 3611 Valley Centre Drive, Suite 300, San Diego, CA 92130.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on March 17, 2025.
What was Travere Therapeutics, Inc. formerly known as?
Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and Desert Gateway, Inc.
In which state was Travere Therapeutics, Inc. incorporated?
Travere Therapeutics, Inc. was incorporated in Delaware.
What is the IRS Employer Identification Number for Travere Therapeutics, Inc.?
The IRS Employer Identification Number for Travere Therapeutics, Inc. is 27-4842691.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 17, 2025 regarding Travere Therapeutics, Inc. (TVTX).